<code id='9E55E9E50F'></code><style id='9E55E9E50F'></style>
    • <acronym id='9E55E9E50F'></acronym>
      <center id='9E55E9E50F'><center id='9E55E9E50F'><tfoot id='9E55E9E50F'></tfoot></center><abbr id='9E55E9E50F'><dir id='9E55E9E50F'><tfoot id='9E55E9E50F'></tfoot><noframes id='9E55E9E50F'>

    • <optgroup id='9E55E9E50F'><strike id='9E55E9E50F'><sup id='9E55E9E50F'></sup></strike><code id='9E55E9E50F'></code></optgroup>
        1. <b id='9E55E9E50F'><label id='9E55E9E50F'><select id='9E55E9E50F'><dt id='9E55E9E50F'><span id='9E55E9E50F'></span></dt></select></label></b><u id='9E55E9E50F'></u>
          <i id='9E55E9E50F'><strike id='9E55E9E50F'><tt id='9E55E9E50F'><pre id='9E55E9E50F'></pre></tt></strike></i>

          entertainment

          entertainment

          author:leisure time    Page View:92
          David L. Ryan/Boston Globe

          A team of high-powered scientists and billionaire investors said Friday that they’re launching a biomedical institute in Cambridge’s Kendall Square with $500 million in private funding with the aim of shortening the path from research breakthroughs to life-saving medicines.

          The institute, called Arena BioWorks, will put drug discovery and company creation under one roof, upending the traditional model where academic research and venture-backed drug development are separate.

          advertisement

          Backed by deep-pocketed investors including Steve Pagliuca, the former co-chair of Bain Capital and Celtics co-owner, and high-tech mogul Michael Dell, Arena has already lured top scientists from academic labs with lucrative compensation packages, but so far has publicly named only a few.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Moonlake's readout produced a cash windfall. Risks remain
          Moonlake's readout produced a cash windfall. Risks remain

          MollyFerguson/STATFortwodaysstartingonSunday,MoonlakeImmunotherapeuticshappilycrunchednumbersandshar

          read more
          The Karikó problem: Lessons for funding basic research
          The Karikó problem: Lessons for funding basic research

          AdobeNewscientificinstitutesarespringingupallovertheplacethesedays:ArcadiaScience,NewScience,ArcInst

          read more
          The cancer drug shortage isn’t new — and neither are the solutions
          The cancer drug shortage isn’t new — and neither are the solutions

          PreparingachemotherapytreatmentatDukeCancerCenterinDurham,N.C.GerryBroome/APAyounggirl,maybe5or6year

          read more

          Kidney transplant patients stopped immunosuppressants in trial

          BRENDANSMIALOWSKI/AFP/GettyImagesKidneytransplantsarethemostcommonorgantransplantprocedureintheU.S.,